{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:25:06Z","timestamp":1790490306747,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The tumor associated antigen (TAA) gp100 was one of the first identified and has been used in clinical trials to treat melanoma patients. However, the gp100 epitope peptide restricted to HLA-A*2402 has not been extensively examined clinically due to the ethnic variations. Since it is the most common HLA Class I allele in the Japanese population, we performed a phase I clinical trial of cancer vaccination using the HLA-A*2402 gp100 peptide to treat patients with metastatic melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The phase I clinical protocol to test a HLA-A*2402 gp100 peptide-based cancer vaccine was designed to evaluate safety as the primary endpoint and was approved by The University of Tokyo Institutional Review Board. Information related to the immunologic and antitumor responses were also collected as secondary endpoints. Patients that were HLA-A*2402 positive with stage IV melanoma were enrolled according to the criteria set by the protocol and immunized with a vaccine consisting of epitope peptide (VYFFLPDHL, gp100-in4) emulsified with incomplete Freund's adjuvant (IFA) for the total of 4 times with two week intervals. Prior to each vaccination, peripheral blood mononuclear cells (PBMCs) were separated from the blood and stored at -80\u00b0C. The stored PBMCs were thawed and examined for the frequency of the peptide specific T lymphocytes by IFN-\u03b3- ELISPOT and MHC-Dextramer assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No related adverse events greater than grade I were observed in the six patients enrolled in this study. No clinical responses were observed in the enrolled patients although vitiligo was observed after the vaccination in two patients. Promotion of peptide specific immune responses was observed in four patients with ELISPOT assay. Furthermore, a significant increase of CD8\n                      <jats:sup>+<\/jats:sup>\n                      gp100-in4\n                      <jats:sup>+<\/jats:sup>\n                      CTLs was observed in all patients using the MHC-Dextramer assay. Cytotoxic T lymphocytes (CTLs) clones specific to gp100-in4 were successfully established from the PBMC of some patients and these CTL clones were capable of lysing the melanoma cell line, 888 mel, which endogenously expresses HLA-restricted gp100-in4.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest this HLA-restricted gp100-in4 peptide vaccination protocol was well-tolerated and can induce antigen-specific T-cell responses in multiple patients. Although no objective anti-tumor effects were observed, the effectiveness of this approach can be enhanced with the appropriate modifications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1479-5876-8-84","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T02:14:21Z","timestamp":1284603261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402"],"prefix":"10.1186","volume":"8","author":[{"given":"Toshiyuki","family":"Baba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marimo","family":"Sato-Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kanamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oyaizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,16]]},"reference":[{"key":"506_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"P van der Bruggen","year":"1991","unstructured":"van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science. 1991, 254: 1643-1647. 10.1126\/science.1840703.","journal-title":"Science"},{"key":"506_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1084\/jem.179.3.921","volume":"179","author":"B Gaugler","year":"1994","unstructured":"Gaugler B, Van Den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on the melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994, 179: 921-930. 10.1084\/jem.179.3.921.","journal-title":"J Exp Med"},{"key":"506_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1074-7613(95)80053-0","volume":"2","author":"P Boel","year":"1995","unstructured":"Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, Van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995, 2: 167-175. 10.1016\/S1074-7613(95)80053-0.","journal-title":"Immunity"},{"key":"506_CR4","first-page":"1445","volume":"59","author":"U Brinkmann","year":"1999","unstructured":"Brinkmann U, Vasmatzis G, Lee B, Pasten I: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res. 1999, 59: 1445-1448.","journal-title":"Cancer Res"},{"key":"506_CR5","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","volume":"94","author":"YT Chen","year":"1997","unstructured":"Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamso B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997, 94: 1914-1918. 10.1073\/pnas.94.5.1914.","journal-title":"Proc Natl Acad Sci USA"},{"key":"506_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.183.3.1185","volume":"183","author":"PF Robbbins","year":"1994","unstructured":"Robbbins PF, Ei-Gamil M, Li YF, kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated \u03b2-catenin gene encodes a gp100-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1994, 183: 1185-1192. 10.1084\/jem.183.3.1185.","journal-title":"J Exp Med"},{"key":"506_CR7","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1073\/pnas.92.17.7976","volume":"92","author":"PG Coulie","year":"1995","unstructured":"Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA. 1995, 92: 7976-7980. 10.1073\/pnas.92.17.7976.","journal-title":"Proc Natl Acad Sci USA"},{"key":"506_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.7652577","volume":"269","author":"T Wolfel","year":"1995","unstructured":"Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995, 269: 1281-1284. 10.1126\/science.7652577.","journal-title":"Science"},{"key":"506_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.180.1.35","volume":"180","author":"PG Coulie","year":"1994","unstructured":"Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T: A new gene encoding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994, 180: 35-42. 10.1084\/jem.180.1.35.","journal-title":"J Exp Med"},{"key":"506_CR10","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1073\/pnas.91.9.3515","volume":"91","author":"Y Kawakami","year":"1994","unstructured":"Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994, 91: 3515-3519. 10.1073\/pnas.91.9.3515.","journal-title":"Proc Natl Acad Sci USA"},{"key":"506_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1084\/jem.178.2.489","volume":"178","author":"V Brichard","year":"1993","unstructured":"Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2melanoma. J Exp Med. 1993, 178: 489-495. 10.1084\/jem.178.2.489.","journal-title":"J Exp Med"},{"key":"506_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1084\/jem.181.2.799","volume":"181","author":"RF Wang","year":"1995","unstructured":"Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 1995, 181: 799-804. 10.1084\/jem.181.2.799.","journal-title":"J Exp Med"},{"key":"506_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1084\/jem.179.3.1005","volume":"179","author":"AB Bakker","year":"1994","unstructured":"Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994, 179: 1005-1009. 10.1084\/jem.179.3.1005.","journal-title":"J Exp Med"},{"key":"506_CR14","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1073\/pnas.91.14.6458","volume":"91","author":"Y Kawakami","year":"1994","unstructured":"Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor regection. Proc Natl Acad Sci USA. 1994, 91: 6458-6462. 10.1073\/pnas.91.14.6458.","journal-title":"Proc Natl Acad Sci USA"},{"key":"506_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0065-2776(08)60431-9","volume":"62","author":"RA Henderson","year":"1996","unstructured":"Henderson RA, Finn OJ: Human tumor antigens are ready to fly. Adv Immunol. 1996, 62: 217-256. full_text.","journal-title":"Adv Immunol"},{"key":"506_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.0.CO;2-W","volume":"75","author":"JN Cormier","year":"1998","unstructured":"Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steunberg SM, Rosenberg SA, Marincola FM: Heterogenous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer. 1998, 75: 517-524. 10.1002\/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.0.CO;2-W.","journal-title":"Int J Cancer"},{"key":"506_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00000478-199805000-00011","volume":"22","author":"A Jungbluth","year":"1998","unstructured":"Jungbluth A, Busam K, Gerald W, Stockert E, Coplan K, Iversen K, MacGregor D, Old L, Chen YT: An anti-Melan-A monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998, 22: 595-602. 10.1097\/00000478-199805000-00011.","journal-title":"Am J Surg Pathol"},{"key":"506_CR18","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.154.8.3961","volume":"154","author":"Y Kawakami","year":"1995","unstructured":"Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995, 154: 3961-3968.","journal-title":"J Immunol"},{"key":"506_CR19","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.4049\/jimmunol.157.6.2539","volume":"157","author":"MR Parkhaust","year":"1996","unstructured":"Parkhaust MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakai Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996, 157: 2539-2548.","journal-title":"J Immunol"},{"key":"506_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nm0398-321","volume":"4","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Duley SL, Schwartz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhon JH, White DE: Immunological and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patient with metastatic melanoma. Nat Med. 1998, 4: 321-327. 10.1038\/nm0398-321.","journal-title":"Nat Med"},{"key":"506_CR21","first-page":"3012","volume":"10","author":"CL Slingluff Jr","year":"2001","unstructured":"Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001, 10: 3012-3024.","journal-title":"Clin Cancer Res"},{"key":"506_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<669::AID-IJC9>3.0.CO;2-#","volume":"82","author":"JC Skipper","year":"1999","unstructured":"Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL: Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer. 1999, 82: 669-677. 10.1002\/(SICI)1097-0215(19990827)82:5<669::AID-IJC9>3.0.CO;2-#.","journal-title":"Int J Cancer"},{"key":"506_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1399-0039.1996.tb02520.x","volume":"47","author":"Y Date","year":"1996","unstructured":"Date Y, Kimura A, Kato H, Sasazuki T: DNA typing of the HLA-A gene: population study and identification of for new alleles in Japan. Tissue Antigens. 1996, 47: 93-101. 10.1111\/j.1399-0039.1996.tb02520.x.","journal-title":"Tissue Antigens"},{"key":"506_CR24","first-page":"1065","volume-title":"HLA","author":"T Imanishi","year":"1992","unstructured":"Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. HLA. 1992, Oxford, United Kingdom: Oxford Scientific Publications, 1: 1065-1220. 1992"},{"key":"506_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4049\/jimmunol.159.1.303","volume":"159","author":"PF Robbins","year":"1997","unstructured":"Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA: The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol. 1997, 159: 303-308.","journal-title":"J Immunol"},{"key":"506_CR26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.152.1.163","volume":"152","author":"KC Parker","year":"1994","unstructured":"Parker KC, Bednarek MA, Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide-side-chains. J Immunol. 1994, 152: 163-175.","journal-title":"J Immunol"},{"key":"506_CR27","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.4049\/jimmunol.159.12.6242","volume":"159","author":"Y Ikeda-Moore","year":"1997","unstructured":"Ikeda-Moore Y, Tomiyama H, Ibe M, Oka S, Miwa K, Kaneko Y, Takiguchi M: Identification and Characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol. 1997, 159: 6242-6252.","journal-title":"J Immunol"},{"key":"506_CR28","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.4049\/jimmunol.154.11.5944","volume":"154","author":"PF Robbins","year":"1995","unstructured":"Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol. 1995, 154: 5944-5950.","journal-title":"J Immunol"},{"key":"506_CR29","first-page":"431","volume":"59","author":"I Kawashima","year":"1999","unstructured":"Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E: Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2\/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 1999, 59: 431-435.","journal-title":"Cancer Res"},{"key":"506_CR30","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","volume":"333","author":"EA Walter","year":"1995","unstructured":"Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Eng J Med. 1995, 333: 1038-1044. 10.1056\/NEJM199510193331603.","journal-title":"N Eng J Med"},{"key":"506_CR31","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1158\/0008-5472.CAN-04-3759","volume":"65","author":"S Wada","year":"2005","unstructured":"Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H: Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005, 65: 4939-4946. 10.1158\/0008-5472.CAN-04-3759.","journal-title":"Cancer Res"},{"key":"506_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/(SICI)1097-0215(19990105)80:1<92::AID-IJC18>3.0.CO;2-M","volume":"80","author":"I Nukaya","year":"1999","unstructured":"Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I: Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999, 80: 92-97. 10.1002\/(SICI)1097-0215(19990105)80:1<92::AID-IJC18>3.0.CO;2-M.","journal-title":"Int J Cancer"},{"key":"506_CR33","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.4049\/jimmunol.157.6.2539","volume":"157","author":"MR Parkhurst","year":"1996","unstructured":"Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996, 157: 2539-2548.","journal-title":"J Immunol"},{"key":"506_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nm0398-321","volume":"4","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998, 4: 321-327. 10.1038\/nm0398-321.","journal-title":"Nat Med"},{"key":"506_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer. 1981, 47: 207-214. 10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6.","journal-title":"Cancer"},{"key":"506_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/01.cji.0000195295.74104.ad","volume":"29","author":"JD Roberts","year":"2006","unstructured":"Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG, Cancer and Leukemia Group B: Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006, 29: 95-101. 10.1097\/01.cji.0000195295.74104.ad.","journal-title":"J Immunother"},{"key":"506_CR37","first-page":"5","volume":"9","author":"J Yuan","year":"2009","unstructured":"Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD: Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immunity. 2009, 9: 5-","journal-title":"Cancer Immunity"},{"key":"506_CR38","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/00003226-200005001-00002","volume":"19","author":"Y Kawakami","year":"2000","unstructured":"Kawakami Y: New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system. Cornea. 2000, 19: S2-6. 10.1097\/00003226-200005001-00002.","journal-title":"Cornea"},{"key":"506_CR39","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","volume":"126","author":"PD Boasberg","year":"2006","unstructured":"Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ: Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. Invest Dermatol. 2006, 126: 2658-2663. 10.1038\/sj.jid.5700545.","journal-title":"Invest Dermatol"},{"key":"506_CR40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1078\/0171-9335-00423","volume":"83","author":"J Steitz","year":"2004","unstructured":"Steitz J, Wenzel J, Gaffal E, T\u00fcting T: Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur J Cell Biol. 2004, 83: 797-803. 10.1078\/0171-9335-00423.","journal-title":"Eur J Cell Biol"},{"key":"506_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0065-2776(06)90007-8","volume":"90","author":"CL Slingluff Jr","year":"2006","unstructured":"Slingluff CL, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH: Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol. 2006, 90: 243-295. full_text.","journal-title":"Adv Immunol"},{"key":"506_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.coi.2005.11.013","volume":"18","author":"P van der Bruggen","year":"2006","unstructured":"van der Bruggen P, Van den Eynde BJ: Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol. 2006, 18: 98-104. 10.1016\/j.coi.2005.11.013.","journal-title":"Curr Opin Immunol"},{"key":"506_CR43","first-page":"4749","volume":"56","author":"ML Salgaller","year":"1996","unstructured":"Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 1996, 56: 4749-4757.","journal-title":"Cancer Res"},{"key":"506_CR44","first-page":"S24","volume":"5","author":"L Craig Jr","year":"2005","unstructured":"Craig L, Slingluff : Melanoma peptide vaccines: multipeptide approaches for targeting cytotoxic and helper T cells. Cancer Immunity. 2005, 5: S24-","journal-title":"Cancer Immunity"},{"key":"506_CR45","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.4049\/jimmunol.163.12.6867","volume":"163","author":"US Kammula","year":"1999","unstructured":"Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol. 1999, 163: 6867-6875.","journal-title":"J Immunol"},{"key":"506_CR46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri1150","volume":"3","author":"OJ Finn","year":"2003","unstructured":"Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003, 3: 630-641. 10.1038\/nri1150.","journal-title":"Nat Rev Immunol"},{"key":"506_CR47","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrc1815","volume":"6","author":"PL Lollini","year":"2006","unstructured":"Lollini PL, Cavallo F, Nanni P, Forni G: Vaccines for tumour prevention. Nat Rev Cancer. 2006, 6: 204-216. 10.1038\/nrc1815.","journal-title":"Nat Rev Cancer"},{"key":"506_CR48","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","volume":"25","author":"Q Gao","year":"2007","unstructured":"Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007, 25: 2586-2593. 10.1200\/JCO.2006.09.4565.","journal-title":"J Clin Oncol"},{"key":"506_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccr.2005.02.013","volume":"7","author":"F Balkwill","year":"2005","unstructured":"Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005, 7: 211-217. 10.1016\/j.ccr.2005.02.013.","journal-title":"Cancer Cell"},{"key":"506_CR50","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2006.02.016","volume":"124","author":"M Karin","year":"2006","unstructured":"Karin M, Lawrence T, Nizet V: Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006, 124: 823-835. 10.1016\/j.cell.2006.02.016.","journal-title":"Cell"},{"key":"506_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE Visser","year":"2006","unstructured":"Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6: 24-37. 10.1038\/nrc1782.","journal-title":"Nat Rev Cancer"},{"key":"506_CR52","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","volume":"14","author":"FO Smith","year":"2008","unstructured":"Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008, 14: 5610-8. 10.1158\/1078-0432.CCR-08-0116.","journal-title":"Clin Cancer Res"},{"key":"506_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00002371-200211000-00002","volume":"25","author":"FJ Hsu","year":"2002","unstructured":"Hsu FJ, Komarovskaya M: CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother. 2002, 25: 455-68. 10.1097\/00002371-200211000-00002.","journal-title":"J Immunother"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-8-84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T06:24:02Z","timestamp":1685773442000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-8-84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,16]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-8-84","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,16]]},"assertion":[{"value":"21 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"84"}}